Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors
This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pan…
Metastatic Pancreatic Neuroendocrine TumorPancreatic NeoplasmStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more
National Cancer Institute (NCI)NCT05687123
Phase 1
A Phase I Study of Fulvestrant in Combination With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
Metastatic Pancreatic Neuroendocrine Tumor
University of ChicagoNCT06663072